Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc.

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Arrowhead Pharmaceuticals yesterday and set a price target of $81.00. ...

Bank of America Securities Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Jefferies analyst maintained a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $67.00. In addition to Jefferies, Arrowhead ...

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research Report)...

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK) and Denali Therapeutics (DNLI)

Arrowhead Pharmaceuticals, Inc. ( ($ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc. pr...

Arrowhead Pharmaceuticals Reports Transformative Year-End Results

In a report released today, from B. Riley Securities reiterated a Buy rating on Arrowhead Pharmaceuticals, with a price target of $61.00. In additi...

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from B. Riley Securities

An announcement from Arrowhead Pharmaceuticals ( ($ARWR) ) is now available. On November 18, 2025, Arrowhead Pharmaceuticals announced that the FDA...

Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARWR	$70.09	-1.03%	1.56M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARWR	$70.09	-1.0%	1.56M
3
4
5
6

ARWR

ARWR

Get Arrowhead Pharmaceuticals Inc. Data in Excel

Get Arrowhead Pharmaceuticals Inc. Data in Excel